X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1274) 1274
Publication (259) 259
Newsletter (115) 115
Book Chapter (10) 10
Newspaper Article (6) 6
Book Review (4) 4
Conference Proceeding (4) 4
Dissertation (4) 4
Reference (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vorinostat (1333) 1333
index medicus (831) 831
humans (774) 774
oncology (467) 467
cancer (450) 450
histone deacetylase inhibitors (334) 334
histone deacetylase inhibitors - pharmacology (326) 326
suberoylanilide hydroxamic acid (324) 324
hydroxamic acids - pharmacology (321) 321
apoptosis (312) 312
cell line, tumor (287) 287
animals (283) 283
female (273) 273
histone deacetylase inhibitor (255) 255
research (234) 234
male (233) 233
expression (226) 226
antineoplastic agents - pharmacology (215) 215
histone deacetylase (202) 202
mice (183) 183
apoptosis - drug effects (181) 181
article (166) 166
acetylation (164) 164
pharmacology & pharmacy (164) 164
saha (164) 164
middle aged (159) 159
hydroxamic acids - administration & dosage (158) 158
care and treatment (157) 157
gene expression (156) 156
cell proliferation - drug effects (152) 152
chemotherapy (150) 150
analysis (146) 146
aged (144) 144
hematology (144) 144
histone deacetylases - metabolism (142) 142
hydroxamic acids - therapeutic use (131) 131
proteins (130) 130
adult (128) 128
combination (122) 122
hdac inhibitors (122) 122
histone deacetylase inhibitors - therapeutic use (122) 122
antineoplastic agents - therapeutic use (120) 120
cell biology (119) 119
health aspects (119) 119
drug therapy (116) 116
epigenetics (109) 109
therapy (107) 107
tumors (104) 104
t-cell lymphoma (103) 103
hdac inhibitor (101) 101
phase-i (101) 101
antineoplastic combined chemotherapy protocols - therapeutic use (98) 98
bortezomib (97) 97
drug synergism (97) 97
biochemistry & molecular biology (96) 96
dose-response relationship, drug (93) 93
histone deacetylase inhibitors - administration & dosage (92) 92
trial (91) 91
valproic acid (91) 91
inhibitors (89) 89
cells (88) 88
chemistry, medicinal (88) 88
clinical trials (87) 87
histones - metabolism (85) 85
treatment outcome (85) 85
in-vitro (84) 84
cell cycle (81) 81
cell survival - drug effects (81) 81
cancer therapies (80) 80
gene-expression (79) 79
hdac (79) 79
hydroxamic acids - adverse effects (78) 78
neoplasms - drug therapy (76) 76
medicine & public health (74) 74
genetic aspects (73) 73
growth (73) 73
activation (71) 71
lymphomas (71) 71
panobinostat (70) 70
romidepsin (70) 70
phase-ii trial (69) 69
lymphoma (68) 68
xenograft model antitumor assays (68) 68
antineoplastic agents (67) 67
medical research (67) 67
t cells (67) 67
breast cancer (65) 65
chromatin (65) 65
histone deacetylase inhibitors - chemistry (65) 65
histones (64) 64
hydroxamic acid (63) 63
antimitotic agents (61) 61
dosage and administration (60) 60
leukemia (60) 60
aged, 80 and over (59) 59
differentiation (59) 59
solid tumors (59) 59
mice, nude (57) 57
gene expression regulation, neoplastic - drug effects (56) 56
genes (56) 56
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1392) 1392
Russian (5) 5
Korean (4) 4
Japanese (2) 2
Catalan (1) 1
French (1) 1
German (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 01/2014, Volume 69, Issue 1, pp. 28 - 33
Journal Article
by Kim, Ellen J and Kim, Youn H and Bagot, Martine and Pinter-Brown, Lauren and Rook, Alain H and Porcu, Pierluigi and Horwitz, Steven M and Whittaker, Sean and Tokura, Yoshiki and Vermeer, Maarten and Zinzani, Pier Luigi and Sokol, Lubomir and Morris, Stephen and Ortiz-Romero, Pablo L and Eradat, Herbert and Scarisbrick, Julia and Tsianakas, Athanasios and Elmets, Craig and Dalle, Stephane and Fisher, David C and Halwani, Ahmad and Poligone, Brian and Greer, John and Fierro, Maria Teresa and Khot, Amit and Moskowitz, Alison J and Musiek, Amy and Shustov, Andrei and Pro, Barbara and Geskin, Larisa J and Dwyer, Karen and Moriya, Junji and Leoni, Mollie and Humphrey, Jeffrey S and Hudgens, Stacie and Grebennik, Dmitri O and Tobinai, Kensei and Duvic, Madeleine and Abhyankar, Sunil and Akilov, Oleg and Alpdogan, Onder and Beylot-Barry, Marie and Boh, Erin and Caballero, Dolores and Cowan, Richard and Dreno, Brigitte and Dummer, Reinhard and Fenske, Timothy and Foss, Francine and Fukuhara, Noriko and Giri, Pratyush and Habe, Koji and Hamada, Toshihisa and Hatake, Kiyohiko and Iida, Shinsuke and Ishikawa, Osamu and Iversen, Lars and Kiyohara, Eiji and Koga, Hiroshi and Korman, Neil and Kuss, Bryone Jean and Lamar, Zanetta and Lansigan, Frederick and Lechowicz, Mary Jo and Lerner, Adam and Magnolo, Nina and Mark, Lawrence and Miyagaki, Tomomitsu and Munoz, Javier and Nicolay, Jan Peter and Nishiwaki, Kaoru and Okamoto, Hiroyuki and Ohtsuka, Mikio and Pacheco, Theresa and Querfeld, Christiane and Rapini, Ronald Peter and Sano, Shigetoshi and Tanaka, Maiko and Tharp, Michael D and Uehara, Jiro and Wada, Hidefumi and Wells, Jillian and Wilcox, Ryan A and William, Basem and Yonekura, Kentaro and MAVORIC Investigators
The Lancet Oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1192 - 1204
Journal Article
Advances in Experimental Medicine and Biology, ISSN 0065-2598, 2018, Volume 1074, pp. 367 - 373
Journal Article
Oncology Reports, ISSN 1021-335X, 04/2019, Volume 41, Issue 4, pp. 2089 - 2102
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 10, pp. 1747 - 1753
[Background]: Epigenome-targeting drugs, for example, histone decetylases (HDACs) inhibitors, have been recently shown to induce apoptosis in a variety of... 
Journal Article
Oncotarget, ISSN 1949-2553, 09/2017, Volume 8, Issue 40, p. 67891
Several histone deacetylase inhibitors including Vorinostat have received FDA approval for the treatment of haematological malignancies. However, data from... 
Journal Article
Journal of drug targeting, ISSN 1061-186X, 2018, Volume 26, Issue 5-6, pp. 448 - 457
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor (HDACI) approved by FDA for the treatment of cutaneous T cell lymphoma, is a promising... 
Prodrug micelles | Co-delivery | Doxorubicin | Vorinostat
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 5, pp. 5703 - 5715
Co-occurrence of and mutations provoke an animal model of AML by epigenetic repression of Wnt pathway antagonists, including and by hyperexpression of encoding... 
AML | Epigenetics | Bortezomib | Sorafenib | Vorinostat
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 10/2014, Volume 57, Issue 20, pp. 8358 - 8377
A systematic study of medicinal chemistry aimed at identifying a new generation of HDAC inhibitors, through the introduction of a thiol zinc-binding group... 
DESIGN | CHEMISTRY, MEDICINAL | ANALOGS | ACIDS | SUBSTRATE | HISTONE DEACETYLASE INHIBITORS | VORINOSTAT
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 04/2018, Volume 275, pp. 117 - 128
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2018, Volume 93, Issue 4, pp. 486 - 493
Loss of major histocompatibility Class II expression (MHCII) in diffuse large B‐cell lymphoma (DLBCL) correlates with decreased survival. MHCII transcription... 
CLASS-II EXPRESSION | SURVIVAL | ACTIVATION | INHIBITION | SUBEROYLANILIDE HYDROXAMIC ACID | R-CHOP | GENES | DIFFERENTIATION | LEUKEMIA | HEMATOLOGY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Histone Deacetylase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Young Adult | HLA-D Antigens - biosynthesis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Cytokines - blood | Doxorubicin - administration & dosage | Rituximab - adverse effects | Prednisone - administration & dosage | Sepsis - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Treatment Outcome | Vorinostat - adverse effects | Febrile Neutropenia - immunology | Rituximab - administration & dosage | Febrile Neutropenia - etiology | Sepsis - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Vincristine - adverse effects | Aged | Vorinostat - administration & dosage | Doxorubicin - adverse effects | Histone Deacetylase Inhibitors - adverse effects | Antimitotic agents | Broadway theater | Care and treatment | Chemotherapy | Lymphomas | Product development | Antineoplastic agents | Cancer | Index Medicus | vorinostat | histone deacetylase inhibitor | diffuse large B-cell lymphoma
Journal Article
American Journal of Translational Research, ISSN 1943-8141, 2011, Volume 3, Issue 2, pp. 166 - 179
Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation,... 
HDAC inhibitor | Depsipeptide (FK228) | MS-275 | Acetylation | Vorinostat (SAHA) | Cancer | acetylation | MEDICINE, RESEARCH & EXPERIMENTAL | depsipeptide (FK228) | ONCOLOGY | cancer | vorinostat (SAHA) | Review
Journal Article
Nano Letters, ISSN 1530-6984, 12/2017, Volume 17, Issue 12, pp. 7684 - 7690
Gefitinib is a first-line therapy in the EGFR-mutated nonsmall cell lung cancer (NSCLC). However, the development of drug resistance is almost unavoidable,... 
gefitinib | drug resistance | vorinostat | nonsmall cell lung cancer | EGFR | Tumor-associated macrophages
Journal Article